The committee, which passed the FDA Reauthorization Act in a 54-0 vote, now advances the bill to the House. The legislation seeks to reauthorize the user fee program, which allows the Food and Drug Administration to collect fees from drug or devicemakers for new product applications. The agency uses these funds to hire more staff and accelerate the approval process, according to the report.
The committee also approved an additional amendment to the bill that would require the FDA to regulate device accessories. Another amendment would establish pilot projects to ensure device reliability, safety and active surveillance data.
The user fee program must be renewed every five years. As the current program expires at the end of September, lawmakers must approve the final bill before the August recess, according to the Washington Examiner.
More articles on supply chain:
4 ways hospitals can lower inpatient drug costs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
